<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623036</url>
  </required_header>
  <id_info>
    <org_study_id>MHUMC 2015.10.01</org_study_id>
    <nct_id>NCT02623036</nct_id>
  </id_info>
  <brief_title>The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors</brief_title>
  <official_title>The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Health University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Health University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use ambulatory blood pressure monitors to investigate whether
      enalapril is superior to lisinopril in managing nocturnal hypertension in patients with
      resistant hypertension currently treated with daytime angiotensin converting enzyme
      inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resistant hypertension is defined as blood pressure &gt; 140/90 mm Hg while adherent to three or
      more antihypertensive medications or &lt; 140/90 mm Hg treated with four or more
      antihypertensives. Patients with resistant hypertension may be at risk for elevated nighttime
      blood pressure &gt;120/70 mm Hg and &quot;non-dipping&quot; (night/day blood pressure &gt; 0.9). A higher
      rate of cardiovascular events occur during the &quot;morning surge&quot; partially attributed elevated
      nighttime blood pressure due to increased renin angiotensin aldosterone system (RAAS)
      activity. Angiotensin converting enzyme inhibitors (ACEIs) suppress RAAS activity

      This prospective randomized parallel-group pilot study will occur at Memorial Family
      Medicine. Eligible patients will undergo three study visits over a 5-8 week span. After
      providing written informed consent, patients will complete an initial screening visit
      assessing 25 hour blood pressure using ambulatory blood pressure monitors. Patients will
      continue the study if they are found to have a nighttime blood pressure &gt;120/70 mm Hg.
      Patients continuing the study will be randomly assigned to equivalent dose lisinopril or
      enalapril treatment arms and their administration time will be changed to &quot;bedtime.&quot; At the
      final visit, patients will complete a final ambulatory blood pressure analysis to reassess
      nighttime blood pressure and dipping status.

      It's expected that patients with enalapril treatment will have superior nighttime blood
      pressure reduction compared to the lisinopril treatment group. If the expected outcome
      occurs, more patients in the enalapril group will meet their nighttime blood pressure goal
      (&lt;120/70 mm Hg) and exhibit a &quot;dipping pattern.&quot; Current evidence suggests that patients with
      normal nighttime blood pressure and dipping pattern are at a lower risk for cardiovascular
      morbidity and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline nighttime blood pressure</measure>
    <time_frame>Baseline and 4-6 weeks</time_frame>
    <description>Average blood pressure between 0000-0600.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline night to day blood pressure ratio (dipping status)</measure>
    <time_frame>Baseline and 4-6 weeks</time_frame>
    <description>Nighttime blood pressure (average 0000-0600)/Daytime blood pressure 0900-2100. This outcomes evaluates patients' circadian blood pressure pattern. A normal circadian blood pressure pattern shows a 10% decrease in both systolic and diastolic blood pressure at night. This will help measure the impact of chronotherapy between the 2 study agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 24 Hour Blood Pressure</measure>
    <time_frame>Baseline and 4-6 weeks</time_frame>
    <description>Average blood pressure over 24 hours (0000-2359)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension, Resistant to Conventional Therapy</condition>
  <arm_group>
    <arm_group_label>Enalapril arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Equivalent dose enalapril</intervention_name>
    <description>Chronotherapy with enalapril.</description>
    <arm_group_label>Enalapril arm</arm_group_label>
    <other_name>Vasotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Equivalent dose lisinopril</intervention_name>
    <description>Chronotherapy with lisinopril</description>
    <arm_group_label>Lisinopril arm</arm_group_label>
    <other_name>Prinivil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinic blood pressure &gt; 140/90 mm Hg on 3 antihypertensives or clinic
             blood pressure &lt; 140/90 mm Hg on 4 antihypertensives

          -  Currently treated with an angiotensin converting enzyme inhibitor

        Exclusion Criteria:

          -  Chronic kidney disease (CKD) stage 4 or worse

          -  Pheochromocytoma

          -  Unstable cardiovascular disease Stroke, Transient Ischemic Attack, Unstable Angina, or
             Myocardial infarction in the last 30 days

          -  Hyperaldosteronism

          -  Current pregnancy

          -  Shift worker at night

          -  Presenting blood pressure &gt; 180/110 mm Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Bucheit, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Health University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John D Bucheit, Pharm.D.</last_name>
    <phone>912-350-8404</phone>
    <email>bucheit_jd@mercer.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Gleit, M.D.</last_name>
    <phone>912-350-8404</phone>
    <email>cindygleit@memorialhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Family Medicine Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Bucheit, Pharm.D.</last_name>
      <phone>312-350-8404</phone>
      <email>bucheit_jd@mercer.edu</email>
    </contact>
    <investigator>
      <last_name>John Bucheit, Pharm.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Gleit, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Momary, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Kaylor, R.N.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Gordon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141.</citation>
    <PMID>18574054</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.</citation>
    <PMID>23817082</PMID>
  </reference>
  <results_reference>
    <citation>Weisser K, Schloos J, Lehmann K, Düsing R, Vetter H, Mutschler E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol. 1991;40(1):95-9.</citation>
    <PMID>1647954</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Memorial Health University Medical Center</investigator_affiliation>
    <investigator_full_name>John Bucheit, Pharm.D.,BCACP, CDE</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chronotherapy</keyword>
  <keyword>angiotensin converting enzyme inhibitors</keyword>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

